Derek Cowsert

News

Potential Prognostic, Predictive Value of Circulating Cell-Free DNA for Patients With Advanced ALK-Positive NSCLC

10/04/2022

A study found circulating cell-free DNA to have potential prognostic or predictive value for patients with advanced ALK-positive NSCLC.

A study found circulating...

10/04/2022

Oncology

News

Genetic/Genomic Mutations Exhibit No Association With Talazoparib Efficacy Among Patients With HER2-Negative BRCA1/2

08/12/2022

Derek Cowsert ;

Study findings demonstrate no link between genetic/genomic characteristics and talazoparib efficacy in patients with HER2-negative BRCA1/2-mutated breast cancer.

Study findings demonstrate no...

08/12/2022

Oncology

News

Impact of Age on Quality of Life After Immune Checkpoint Inhibitor Treatment for Patients With Lung Cancer

02/07/2023

Derek Cowsert ;

A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.

A study found old age to be a...

02/07/2023

Oncology

News

Fulvestrant Plus Capivasertib Extends Survival in ER-Positive, HER2-Negative Breast Cancer

07/05/2022

Derek Cowsert ;

Study findings suggest fulvestrant plus capivasertib yielded consistently longer OS and PFS among patients with ER-positive, HER2-negative advanced breast cancer.

Study findings suggest...

07/05/2022

Oncology

News

Neoadjuvant Nivolumab Plus Chemotherapy Improves EFS vs Chemotherapy Alone in Resectable NSCLC

06/13/2022

Derek Cowsert ;

Neoadjuvant nivolumab plus chemotherapy prolonged EFS and yielded a higher percentage of patients with a pathological complete response vs chemotherapy alone among patients with resectable NSCLC in a phase 3 study.

Neoadjuvant nivolumab plus...

06/13/2022

Oncology

News

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC and Solid Tumors

09/22/2022

Derek Cowsert ;

On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...

On September 21, 2022, the FDA...

09/22/2022

Oncology

News

Pembrolizumab Plus Chemotherapy Improves Long-Term Survival Outcomes in Metastatic NSCLC

03/21/2023

Derek Cowsert ;

Updated study results find pembrolizumab plus chemotherapy exhibits long-term survival benefit for patients with metastatic squamous non-small cell lung cancer.

Updated study results find...

03/21/2023

Oncology

News

Driver Variations Associated With Shorter PFS in Patients With NSCLC Receiving Chemoradiation and Durvalumab

07/06/2022

Derek Cowsert ;

A phase 3 cohort study identified driver variations associated with shorter PFS among patients with NSCLC receiving definitive chemoradiation and consolidative durvalumab, highlighting the need for alternative treatment options for these...

A phase 3 cohort study...

07/06/2022

Oncology

“En Face” Freezing Proves Reliable, Safe in Reduction of Tumor Relapse in Patients With Skin Carcinomas

09/20/2022

Derek Cowsert ;

Use of the “en face” freezing technique yields low tumor relapse and guarantees negative surgical margins for patients with skin carcinomas.

Use of the “en face” freezing...

09/20/2022

Oncology

News

Lorlatinib Significantly Improves Survival vs Crizotinib in Patients With ALK-Positive Advanced NSCLC Regardless of Brain Metastases

07/12/2022

Derek Cowsert ;

Lorlatinib was associated with improved PFS vs crizotinib among patients with ALK-positive advanced NSCLC, with or without brain metastases, according to findings from the phase 3 CROWN study.

Lorlatinib was associated with...

07/12/2022

Oncology